Patents
2021.04.21
TAHO's TAH9922 Atomoxetine oral solution product patent obtained a US patent license.
The TAH9922 Atomoxetine oral solution product patent developed by TAHO, has been approved by the U.S. Patent and Trademark Office for a U.S. patent.
About TAH9922
TAH9922 is an oral liquid for children with ADHD. In order to avoid the difficulty of swallowing the tablet, it was developed into a liquid to facilitate children's intake and facilitate medication to children.
According to IMS Data in 2015, the total market size of pediatric ADHD drugs in the United States is approximately NT$31 billion. The revenue generated by the new dosage form of Atomoxetine drug developed by TAHO will vary by the actual licensing or sales situation in the future.
About TAH9922
TAH9922 is an oral liquid for children with ADHD. In order to avoid the difficulty of swallowing the tablet, it was developed into a liquid to facilitate children's intake and facilitate medication to children.
According to IMS Data in 2015, the total market size of pediatric ADHD drugs in the United States is approximately NT$31 billion. The revenue generated by the new dosage form of Atomoxetine drug developed by TAHO will vary by the actual licensing or sales situation in the future.